BTWM
BMRN icon

Baker Tilly Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Baker Tilly Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,383
Closed -$383K – 297
2024
Q1 		$383K Buy
4,383
+52
+1% +$4.66K 0.07% 308
2023
Q4 		$418K Sell
4,331
-239
-5% -$21.1K 0.07% 325
2023
Q3 		$404K Buy
+4,570
New +$407K 0.07% 306

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Baker Tilly Wealth Management's BMRN Position: Q2 2024 in Review

Baker Tilly Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 4,383 shares — an estimated $383K sold.

Baker Tilly Wealth Management first reported a position in BMRN in Q3 2023 and held it in 3 quarters. The position peaked at $418K in Q4 2023. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

  • Baker Tilly Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Baker Tilly Wealth Management sold 4,383 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $383K.
  • Baker Tilly Wealth Management first reported a position in BioMarin Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • Baker Tilly Wealth Management's BioMarin Pharmaceuticals position peaked at $418K in Q4 2023.
  • 558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Baker Tilly Wealth Management's 13F filing for Q2 2024, filed 18 Jul 2024.